These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26976292)

  • 1. Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States.
    Stoecker C; Kim L; Gierke R; Pilishvili T
    J Gen Intern Med; 2016 Aug; 31(8):901-8. PubMed ID: 26976292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
    Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
    JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.
    Feldman C; Dlamini SK; Madhi SA; Meiring S; von Gottberg A; de Beer JC; de Necker M; Stander MP
    PLoS One; 2020; 15(1):e0227945. PubMed ID: 31995597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program.
    Stoecker C; Kobayashi M; Matanock A; Cho BH; Pilishvili T
    Vaccine; 2020 Feb; 38(7):1770-1777. PubMed ID: 31889609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium.
    Willem L; Blommaert A; Hanquet G; Thiry N; Bilcke J; Theeten H; Verhaegen J; Goossens H; Beutels P
    Hum Vaccin Immunother; 2018 May; 14(5):1218-1229. PubMed ID: 29420161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.
    Choi MJ; Kang SO; Oh JJ; Park SB; Kim MJ; Cheong HJ
    Hum Vaccin Immunother; 2018; 14(8):1914-1922. PubMed ID: 29953307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine.
    Gouveia M; Jesus G; Inês M; Costa J; Borges M
    Hum Vaccin Immunother; 2019; 15(4):850-858. PubMed ID: 30633615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
    Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
    Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
    Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of pneumococcal vaccines for adults in the United States.
    Chen J; O'Brien MA; Yang HK; Grabenstein JD; Dasbach EJ
    Adv Ther; 2014 Apr; 31(4):392-409. PubMed ID: 24718851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions.
    Kobayashi M; Stoecker C; Xing W; Cho BH; Pilishvili T
    Hum Vaccin Immunother; 2021 Jul; 17(7):2232-2240. PubMed ID: 33499718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
    Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
    Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
    Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
    Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults.
    Atwood M; Beausoleil L; Breton MC; Laferriere C; Sato R; Weycker D
    Can J Public Health; 2018 Dec; 109(5-6):756-768. PubMed ID: 29981104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
    Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
    PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
    Guo J; Zhang H; Zhang H; Lai X; Wang J; Feng H; Fang H
    Vaccine; 2023 Jan; 41(3):716-723. PubMed ID: 36522264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.